The liquidators of Gold Coast fund manager Equititrust are seeking court approval of a confidential settlement of two proceedings brought against KPMG for allegedly failing to properly audit the firm prior to its collapse.
A judge has found a senior female partner at Piper Alderman has not provided sufficient evidence that the firm moved to oust her from its ranks because she is a woman, in a ruling dismissing her bid for an order halting the firm from moving forward with a meeting on the proposed expulsion.
The lead applicant in a shareholder class action against global engineering firm CIMIC Group has made a bid for indemnity costs, after a last-minute subpoena of three former executives led to the trial being vacated.
Former IOOF chairman George Venardos will be allowed to object to incriminating evidence and discovery in proceedings brought by APRA, after a court found there was a real and appreciable risk that ASIC could also bring a civil case against him.
APRA has been ordered to hand over all of its correspondence with fellow regulator ASIC relating to former IOOF chairman George Venardos, as he prepares to argue privilege over discovery that might incriminate him in any possible ASIC proceedings.
The consumer regulator wants a court to throw out Ultra Tune’s appeal of a $2.6 million penalty after the national car repair franchise filed its challenge more than a month late because its lawyers “miscalculated” the deadline.
An appeals court has handed a win to the Fair Work Ombudsman in its battle for a multimillion dollar penalty against the CFMEU for coordinated strikes at two Hutchison Ports shipping terminals, finding a judge’s fine of just $38,000 did not cut it.
The former chairman of troubled IOOF told APRA during a review meeting that he “struggled” to think the wealth manager had any conflicts of interest and that the issue was getting too much “airplay”, according to court documents filed recently by the prudential regulator.
Generic drug maker Sandoz has secured a retroactive licence to manufacture a cheaper version of top-selling antidepressant Lexapro, the drug at the heart of a long-running patent infringement battle with pharmaceutical giant Lundbeck.
Global pharmaceutical giant Lundbeck has launched a bid to escape a prior undertaking blocking it from appealing a court’s decision that allowed four generic drug makers to apply for licences to manufacture generic versions of popular antidepressant Lexapro.